On September 26, 2025, uniQure N.V. announced that it has commenced a $200 million underwritten public offering of its ordinary shares, with the offering also including pre‑funded warrants to purchase shares in lieu of ordinary shares for certain investors. The offering is being managed by a consortium of bookrunning managers, including Leerink Partners, Stifel, Van Lanschot Kempen and Guggenheim Securities, and is subject to market conditions and other customary closing conditions. The proceeds from the offering are intended to provide additional liquidity to support the company’s late‑stage development and potential commercialization of its lead gene‑therapy candidate, AMT‑130, for Huntington’s disease.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.